C-RBFENAD+ precursors, liposomal delivery, bioactive ingredients
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Provide a healthy-aging bioactive ingredient related to NAD+ support.
NMNH bioactive ingredient offered within EffePharm's healthy-aging product portfolio.
Listed as one of EffePharm's products/platforms in supplied site analysis.
Support healthy aging and NAD+ through a science-backed NMN branded ingredient.
NMN bioactive ingredient for nutrition and healthy-aging applications, supported by an NMN white paper and clinical/scientific positioning.
Won the 2020 “NEW POWER” Innovation Award for the NMN brand material UTHEVER.
Awarded for innovation; supplied material states EffePharm funds anti-aging human health research at Fudan University, Sichuan University, and Tianjin Medical University.
Fund research on anti-aging and human health and generate ideas for human health development.
External research funding at Fudan University, Sichuan University, and Tianjin Medical University.
Publicly stated in 2020 that EffePharm has funded and would continue to fund anti-aging human health research at the named universities.
Develop and apply NMN in pharmaceutical fields, including cancer adjuvant drugs and other disease treatment projects.
Research collaboration or development activity with enterprises and pharmaceutical research institutes focused on NMN applications.
Supplied public record states EffePharm has worked with enterprises and pharmaceutical research institutes to develop and apply NMN in pharmaceutical fields.
Support delivery of bioactive ingredients using micelle-based formulation technology.
Micelles technology platform for bioactive ingredient dispersion or delivery.
Listed by the company as one of its product and platform technologies.
Improve delivery and absorption of bioactive ingredients through micelle technology.
Micelle-based delivery technology platform.
Listed as one of EffePharm's product and platform technologies.
Support EffePharm's delivery and formulation technologies for bioactive ingredients.
Platform associated with LipoAvail liposomal technology, CelleSperse micelles technology, and EncapCirc microencapsulation technology.
Listed as an EffePharm platform in supplied site and public-record material.
Enable delivery or stabilization of bioactive ingredients through microencapsulation.
Microencapsulation technology platform for ingredient formulation.
Listed by the company as one of its product and platform technologies.
Improve stability and delivery of bioactive ingredients through microencapsulation.
Microencapsulation technology platform.
Listed as one of EffePharm's product and platform technologies.
Improve delivery and bioavailability of bioactive ingredients using liposomal formulations.
Liposomal delivery technology for ingredient formulation.
Company lists LipoAvail as a delivery platform and provides liposome white papers.
Improve bioavailability, stability, and absorption of bioactive ingredients using liposomal delivery.
Liposomal delivery technology platform for nutrition, personal care, and liposomal product applications.
Listed as a core EffePharm delivery technology and supported by a Liposome White Paper.
Fund anti-aging human health research and support development/application of NMN in pharmaceutical and disease-treatment contexts.
Company-funded research collaborations or support at Fudan University, Sichuan University, and Tianjin Medical University.
EffePharm reported that it has funded and would continue to fund anti-aging human health research at named universities.